Pharma companies involved in the sale of heartburn therapy Zantac have won a key battle in litigation brought by patients who claim the drug caused them to develop cancer.
GSK has reported much-needed progress with two of its cancer therapies, with a phase 3 trial win for immunotherapy Jemperli in endometrial cancer and the start of a review in the EU for mye
GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US
Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up.
The 2022 edition of the Access to Medicine Index (ATMI) – which places the top 20 pharma companies for their efforts to improve delivery of medicines to lower income countries – sees GSK re
